{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:34:19Z","timestamp":1791920059378,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00198-022-06544-2","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T07:03:06Z","timestamp":1664434986000},"page":"2527-2536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Romosozumab efficacy and safety in European patients enrolled in the FRAME trial"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-7199","authenticated-orcid":false,"given":"Bente","family":"Langdahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz C.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Fahrleitner-Pammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Gielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Czerwinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban J\u00f3dar","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen","family":"Timoshanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Oates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Libanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"6544_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/TCRM.S72456","volume":"10","author":"AS Nazrun","year":"2014","unstructured":"Nazrun AS, Tzar MN, Mokhtar SA, Mohamed IN (2014) A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag 10:937\u2013948. https:\/\/doi.org\/10.2147\/TCRM.S72456","journal-title":"Ther Clin Risk Manag"},{"key":"6544_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.maturitas.2010.09.002","volume":"67","author":"TACM Laurs-van Geel","year":"2010","unstructured":"Laurs-van Geel TACM, Center JR, Geusens PP, Dinant G-J, Eisman JA (2010) Clinical fractures cluster in time after initial fracture. Maturitas 67:339\u2013342. https:\/\/doi.org\/10.1016\/j.maturitas.2010.09.002","journal-title":"Maturitas"},{"key":"6544_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui L-Y et al (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34:632\u2013642. https:\/\/doi.org\/10.1002\/jbmr.3641","journal-title":"J Bone Miner Res"},{"key":"6544_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326. https:\/\/doi.org\/10.1002\/jbmr.173","journal-title":"J Bone Miner Res"},{"key":"6544_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","volume":"8","author":"DM Black","year":"2020","unstructured":"Black DM, Bauer DC, Vittinghoff E et al (2020) Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol 8:672\u2013682. https:\/\/doi.org\/10.1016\/S2213-8587(20)30159-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6544_CR6","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"6544_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33:1219\u20131226. https:\/\/doi.org\/10.1002\/jbmr.3427","journal-title":"J Bone Miner Res"},{"key":"6544_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 34:419\u2013428. https:\/\/doi.org\/10.1002\/jbmr.3622","journal-title":"J Bone Miner Res"},{"key":"6544_CR9","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/jbmr.3439","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C, Milmont CE, Meisner PD, Libanati C, Grauer A (2018) Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res 33:1407\u20131416. https:\/\/doi.org\/10.1002\/jbmr.3439","journal-title":"J Bone Miner Res"},{"key":"6544_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1359\/jbmr.041007","volume":"20","author":"E Barrett-Connor","year":"2005","unstructured":"Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, Santora AC, Sherwood LM (2005) Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 20:185\u2013194. https:\/\/doi.org\/10.1359\/jbmr.041007","journal-title":"J Bone Miner Res"},{"key":"6544_CR11","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Od\u00e9n A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239\u20132256. https:\/\/doi.org\/10.1007\/s00198-012-1964-3","journal-title":"Osteoporos Int"},{"key":"6544_CR12","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s11999-011-1863-5","volume":"469","author":"JA Cauley","year":"2011","unstructured":"Cauley JA (2011) Defining ethnic and racial differences in osteoporosis and fragility fractures. Clin Orthop Relat Res 469:1891\u20131899. https:\/\/doi.org\/10.1007\/s11999-011-1863-5","journal-title":"Clin Orthop Relat Res"},{"key":"6544_CR13","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00198-020-05815-0","volume":"32","author":"EV McCloskey","year":"2021","unstructured":"McCloskey EV, Johansson H, Harvey NC, Lorentzon M, Shi Y, Kanis JA (2021) Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos Int 32:1601\u20131608. https:\/\/doi.org\/10.1007\/s00198-020-05815-0","journal-title":"Osteoporos Int"},{"key":"6544_CR14","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.3390\/nu14132656","volume":"14","author":"J Xu","year":"2022","unstructured":"Xu J, Li S, Zeng Y, Si H, Wu Y, Zhang S, Shen B (2022) Assessing the association between important dietary habits and osteoporosis: a genetic correlation and two-sample mendelian randomization study. Nutrients 14:2656. https:\/\/doi.org\/10.3390\/nu14132656","journal-title":"Nutrients"},{"key":"6544_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06435-6","author":"L Vandenput","year":"2022","unstructured":"Vandenput L, Johansson H, McCloskey EV et al (2022) Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-022-06435-6","journal-title":"Osteoporos Int"},{"key":"6544_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11657-019-0644-8","volume":"14","author":"E Lopez Gavilanez","year":"2019","unstructured":"Lopez Gavilanez E, Johansson H, McCloskey E, Harvey NC, Segale Bajana A, Marriott Blum D, Navarro Grijalva M, Diaz Curiel M, Kanis JA (2019) Assessing the risk of osteoporotic fractures: the Ecuadorian FRAX model. Arch Osteoporos 14:93. https:\/\/doi.org\/10.1007\/s11657-019-0644-8","journal-title":"Arch Osteoporos"},{"key":"6544_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00198-011-1852-2","volume":"23","author":"A Lalmohamed","year":"2012","unstructured":"Lalmohamed A, Welsing PMJ, Lems WF, Jacobs JWG, Kanis JA, Johansson H, De Boer A, De Vries F (2012) Calibration of FRAX \u00ae 3.1 to the Dutch population with data on the epidemiology of hip fractures. Osteoporos Int 23:861\u2013869. https:\/\/doi.org\/10.1007\/s00198-011-1852-2","journal-title":"Osteoporos Int"},{"key":"6544_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00223-013-9717-7","volume":"93","author":"JJ Jaller-Raad","year":"2013","unstructured":"Jaller-Raad JJ, Jaller-Char JJ, Lechuga-Ortiz JA, Navarro-Lechuga E, Johansson H, Kanis JA (2013) Incidence of hip fracture in Barranquilla, Colombia, and the development of a Colombian FRAX model. Calcif Tissue Int 93:15\u201322. https:\/\/doi.org\/10.1007\/s00223-013-9717-7","journal-title":"Calcif Tissue Int"},{"key":"6544_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s11657-015-0224-5","volume":"10","author":"CA Zerbini","year":"2015","unstructured":"Zerbini CA, Szejnfeld VL, Abergaria BH, McCloskey EV, Johansson H, Kanis JA (2015) Incidence of hip fracture in Brazil and the development of a FRAX model. Arch Osteoporos 10:224. https:\/\/doi.org\/10.1007\/s11657-015-0224-5","journal-title":"Arch Osteoporos"},{"key":"6544_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11657-021-00965-y","volume":"16","author":"M Kebaetse","year":"2021","unstructured":"Kebaetse M, Nkhwa S, Mogodi M et al (2021) A country-specific FRAX model for Botswana. Arch Osteoporos 16:90. https:\/\/doi.org\/10.1007\/s11657-021-00965-y","journal-title":"Arch Osteoporos"},{"key":"6544_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC, Od\u00e9n A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775\u2013780. https:\/\/doi.org\/10.1007\/s00198-016-3868-0","journal-title":"Osteoporos Int"},{"key":"6544_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00198-018-4687-2","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Chines A, Brandi ML, Papapoulos S, Lewiecki EM, Reginster JY, Mu\u00f1oz Torres M, Wang A, Bone HG (2019) The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. Osteoporos Int 30:71\u201378. https:\/\/doi.org\/10.1007\/s00198-018-4687-2","journal-title":"Osteoporos Int"},{"key":"6544_CR23","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/jbmr.1606","volume":"27","author":"EV McCloskey","year":"2012","unstructured":"McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27:1480\u20131486. https:\/\/doi.org\/10.1002\/jbmr.1606","journal-title":"J Bone Miner Res"},{"key":"6544_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","volume":"103","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209\u2013215. https:\/\/doi.org\/10.1016\/j.bone.2017.07.005","journal-title":"Bone"},{"key":"6544_CR25","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/s0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594. https:\/\/doi.org\/10.1016\/s0140-6736(17)31613-6","journal-title":"Lancet"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06544-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06544-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06544-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T09:09:45Z","timestamp":1668157785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06544-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6544"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06544-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"22 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BL: received fees and honoraria for lectures and advice from Amgen, Eli Lilly, Gedeon-Richter, Gilead and UCB Pharma; research grants for Aarhus University Hospital from Amgen and Novo Nordisk. LCH: received advisory board honoraria from Alexion, Amgen, Kyowa Kirin International, Shire and UCB Pharma. SF: support from Agnovos, Alexion, Amgen and UCB Pharma; consultant for Agnovos, Alexion, Amgen, Boehringer, Labatec, Myovant, Radius and UCB Pharma. ZW: employee of Amgen and stockholder of Amgen. AFP: research grants (to institution): Amgen, Roche; consultancy\/lecture\/advisory board fees: Alexion, Amgen, Eli Lilly, Fresenius, Gedeon-Richter, Genericon, Ipsen, Ratiopharm, Roche, Sandoz, Sanofi-Aventis, Shire-Takeda, Stada and UCB Pharma. EG: consultancy fees, lecture fees and\/or travel fees from Alexion, Amgen, Sandoz, Takeda and UCB Pharma. PL: grants and\/or advisor from Amgen, UCB Pharma, Richter and Teva. EC: grants from Amgen. EJG: consultancy and\/or speaker and\/or Investigator for Amgen, Asofarma, Astellas, AstraZeneca, Boehringer, BMS, FAES, Helios-Fresenius, Italfarmaco, Janssen, Lilly, MSD, Mundipharma, Novo Nordisk, Sanofi, Shire, Technopharma, UCB Pharma and Viatris. JT: employee of UCB Pharma and stockholder of UCB Pharma. MO: employee of Amgen. CL: employee of UCB Pharma and stockholder of UCB Pharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}